Figure 3.

Reasons for delaying bisphosphonate treatment in patients with bone metastases/lesions, by malignancy type and by country in patients with (A) solid tumours and (B) haematological malignancies: data from the detailed questionnaire. Anti‐tumour treatment included radiotherapy, hormonal therapy, chemotherapy and targeted therapy. Safety concerns included existing renal impairment, to avoid renal deterioration and dental health issues. Patient profile included poor performance status and short life expectancy prognosis. Bone lesion characteristics included low risk of fracture/compression, no pain and pain controlled by analgesics. Investigators could give more than one response.